Business Development Deal Architecture
  • Search OnBioBD:

  • OnBioBD OldSkool NEWS:

    - OnBioVC 4Q11 Trend Analysis, now available
    - OnBioVC 1Q12 White Paper, now available
    - OnBioVC 1Q12 Trend Analysis, coming soon

  • FDA Registered Contract Manufacturer

July 2013, Array BioPharma (ARRY) entered into a Drug Discovery Collaboration Agreement with Loxo Oncology (LOXO) @LoxoOncology, and granted Loxo exclusive rights to develop and commercialize certain Array invented compounds targeted at the tropomyosin kinase (“Trk”) family of receptors, including LOXO-101. In April 2014 and again in April 2015, Array and Loxo amended the agreement […]

July 2013, Array BioPharma (ARRY) and Celgene Corporation (CELG) and Celgene Alpine Investment Co., LLC (collectively “Celgene”) entered into a Drug Discovery and Development Option and License Agreement to collaborate on development of an Array invented preclinical development program targeting a novel inflammation pathway. The agreement provides Celgene an option to select multiple clinical development […]

November 2013, Clovis Oncology ($CLVS @ClovisOncology) acquired Ethical Oncology Science, S.p.A. (“EOS”) (known as Clovis Oncology Italy S.r.l., or “COI”) through which the rights to lucitanib were obtained. 2008, EOS had in-licensed exclusive development and commercial rights to lucitanib on a global basis, excluding China, from Advenchen Laboratories. September 2012, EOS entered into a collaboration and license […]

  

to top of page...